Sometimes, life-saving treatments have serious negative consequences. This month, AMA Journal of Ethics digital editor Amelia Thomson-DeVeaux discusses strategies for communicating about iatrogenic outcomes with Dr. Robert Nelson, a senior pediatric ethicist with the Food and Drug Administration, with a particular focus on how to enlist parents as allies in high-stress pediatric cases.
Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.